Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2009 | 06-2009 | 03-2009 | 12-2008 | 09-2008 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -45,696 | -31,785 | -14,725 | -48,654 | -31,829 |
| Depreciation Amortization | 1,049 | 680 | 329 | 1,048 | 757 |
| Accounts receivable | 5,675 | 6,371 | 6,788 | -6,485 | -716 |
| Other Working Capital | 12,546 | 14,534 | 9,793 | 8,532 | 1,836 |
| Other Operating Activity | -2,754 | -4,498 | -5,963 | 10,185 | 3,617 |
| Operating Cash Flow | $-29,181 | $-14,698 | $-3,779 | $-35,374 | $-26,335 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -898 | -747 | -319 | -1,160 | -907 |
| Investing Cash Flow | $-898 | $-747 | $-319 | $-1,160 | $-907 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 43,998 | 40,969 | 2,448 | 2,570 | 2,056 |
| Financing Cash Flow | $43,998 | $40,969 | $2,448 | $2,570 | $2,056 |
| Beginning Cash Position | 63,716 | 63,716 | 63,716 | 97,679 | 97,679 |
| End Cash Position | 77,636 | 89,241 | 62,065 | 63,716 | 72,493 |
| Net Cash Flow | $13,920 | $25,525 | $-1,651 | $-33,963 | $-25,186 |
| Free Cash Flow | |||||
| Operating Cash Flow | -29,181 | -14,698 | -3,779 | -35,374 | -26,335 |
| Capital Expenditure | -898 | -747 | -319 | -1,160 | -907 |
| Free Cash Flow | -30,078 | -15,444 | -4,098 | -36,534 | -27,242 |